SecBot SecBot

PCVX drug pipeline

Vaxcyte, Inc. · 2 rated drugs
$63.37
−2.0% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
3
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 (adult); Phase 2 (infant)
Time to marketVaxcyte plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2028, pending completion of OPUS-2, OPUS-3, and a manufacturing consistency study. Assuming a standard 10-12 month FDA review, potential approval would be in the 2029 timeframe at the earliest.

VAX-31 31-valent pneumococcal conjugate vaccine Updated Nov 6

What to watch

Watch for OPUS-2 and OPUS-3 topline data in H1 2027, which will complete the adult Phase 3 package. Positive results would clear the path for BLA submission in H1 2028. The key risk to monitor is whether the serotype 3 and 12F noninferiority nuance versus Capvaxive becomes a regulatory or commercial issue. The stock has already had its primary binary catalyst (OPUS-1), so subsequent readouts are expected to be supportive but less dramatic movers.

Bull case
  • OPUS-1 met every prespecified primary endpoint, matching or beating the two leading adult PCV vaccines (Prevnar 20 and Capvaxive) on immunogenicity in a 4,047-patient trial, which drove a ~36% single-day stock gain on October 5, 2026.
  • VAX-31 covers 31 serotypes, the broadest pneumococcal vaccine candidate in development, versus 20 (Prevnar 20) and 21 (Capvaxive) in currently marketed adult vaccines, addressing a large unmet need as serotype replacement drives residual disease.
  • The adult pneumococcal vaccine market is estimated at roughly $8 billion annually, with Pfizer's Prevnar franchise generating $6.49 billion in 2025 and Merck's Capvaxive at $759 million, giving VAX-31 a large addressable market if approved.
Bear case
  • VAX-31 missed the stricter noninferiority bar (LBCI >0.667) on serotypes 3 and 12F versus Capvaxive, though both met the historical LBCI >0.5 threshold; this could be a focus of FDA review or physician adoption concerns.
  • BLA submission is not expected until the first half of 2028, meaning no FDA approval decision is likely before 2029, leaving the stock without a near-term regulatory catalyst and exposed to execution risk across multiple remaining trials.
  • The company is pre-revenue and burning cash rapidly (Q3 2026 net loss of $297 million, R&D expense of $270 million), and while the $3.4B cash position is substantial, the burn rate is accelerating.
● neutral
Impact
PhasePhase 1
Time to marketVAX-A1 is in Phase 1 testing with topline data expected in the second half of 2027. If Phase 1 is successful, the drug would need to complete Phase 2 and Phase 3 trials before any regulatory submission, placing a potential approval many years away (likely 2030 or later, assuming success at every stage).

VAX-A1 Updated Nov 6

What to watch

The next catalyst for VAX-A1 is the Phase 1 topline safety, tolerability and immunogenicity data readout expected in the second half of 2027. Positive data would validate Vaxcyte's platform in a new bacterial target (Group A Strep) and open a large unserved market, but Phase 1 readouts are early-stage and the stock's primary driver remains the VAX-31 pneumococcal franchise. The Q3 2026 earnings update noted the study advanced to Stage 2 after a positive DSMB review of Stage 1 safety data, a modest incremental positive.

Bull case
  • There is currently NO approved vaccine for Group A Streptococcus, which causes over 500,000 deaths annually worldwide. VAX-A1 targets a large, completely unserved market.
  • VAX-A1 is a multicomponent conjugate vaccine designed to provide broad, strain-independent protection, potentially overcoming the antigenic diversity that has stymied prior Strep A vaccine efforts.
  • The Phase 1 study advanced to Stage 2 after an independent DSMB review of Stage 1 safety data, suggesting no early safety signals that would halt development.
Bear case
  • VAX-A1 is only in Phase 1, with topline data not expected until the second half of 2027, leaving years before any potential approval. The vast majority of Phase 1 vaccine candidates fail to reach the market.
  • Vaxcyte's stock is dominated by its pneumococcal conjugate vaccine franchise (VAX-31/VAX-24), which accounts for essentially all of the company's valuation. Even positive VAX-A1 data would likely have a muted impact on the share price.
  • Multiple hedge funds and institutional investors trimmed or exited PCVX positions in Q2 2026 (Farallon, Baupost, Point72, Millennium, Jennison), and insiders sold shares in October/November 2026, though many sales were part of 10b5-1 plans.

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VAX-31Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationPhase 3Completed752Oct 25, 2026
VAX-31A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgePhase 3Completed1,390Oct 21, 2026
31 valent pneumococcal conjugate vaccineSafety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49Phase 3Completed4,049Sep 17, 2026